200 Inner Belt Road
About Finch TherapeuticsFinch Therapeutics is a mission-driven biopharmaceutical company that aims to develop novel microbial therapies serving patients with serious and unmet medical needs. Founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome, Finch uses machine-learning algorithms informed by high-throughput molecular data to reverse engineer successful experiences with fecal transplantation. Through this and other clinical datasets, Finch identifies the microbes that drive desirable clinical outcomes, and develops therapies that deliver those microbial communities to patients. FIN-403 is both Finch’s lead clinical program and a valuable tool for its broader human-first discovery strategy.
CEO: Mark Smith
COO: Andrew Noh
CFO: Susan Clancy
Please click here for Finch job opportunities.
Please click here for clinical trial information.
18 articles with Finch Therapeutics
Finch Therapeutics Presents Data from Its Positive PRISM3 Trial of CP101 in Recurrent C. difficile Infection at Two Leading Medical Conferences
Finch Therapeutics Presents Data from Its Positive PRISM3 Trial of CP101 in Recurrent C. difficile Infection at Two Leading Medical Conferences PRISM3 data presented at the annual meetings of the United European Gastroenterology and the American College of Gastroenterology Late-breaker oral presentations expand on previously announced positive topline data showing that CP101 met the primary efficacy endpoint with statistically significant improv
Finch Therapeutics Announces $90 Million Financing to Advance Pipeline of Investigational Oral Microbiome Drugs
Proceeds to support the advancement of lead candidate through the final stages of clinical development for recurrent C. difficile infection, and the advancement into the clinic of programs for autism spectrum disorder and chronic hepatitis B SOMERVILLE, Mass.--( BUSINESS WIRE )-- Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome drug development company, announced today a $90 million Series D financing. New investors in the roun
The company plans to use the funds to advance its lead candidate CP101 for recurrent C. difficile infection through the final stages of clinical development and regulatory submission.
Finch Therapeutics Announces Positive Topline Results from Randomized Controlled Trial of CP101, an Oral Microbiome Drug, for the Prevention of Recurrent C. difficile Infection
CP101 met the primary efficacy endpoint with statistically significant improvement in the prevention of recurrent C. difficile infection over standard of care alone in a 206-patient trial
Finch Therapeutics reported positive topline results from PRISM3, its Phase II trial of CP101, an oral microbiome drug for the prevention of recurrent C. difficile infection.
Finch Therapeutics Completes Enrollment in Potentially Pivotal Trial of CP101, an Investigational Oral Full-Spectrum Microbiota® Therapy for the Prevention of Recurrent C. difficile Infection
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced that it has completed enrollment in PRISM3, its multi-center, placebo-controlled Phase 2 clinical trial evaluating CP101.
Finch Therapeutics & Takeda Expand Collaboration to Develop Microbiome Therapeutics Using Finch’s Human-First Discovery® Platform
Finch & Takeda to target Crohn’s disease under expanded collaboration
Finch Therapeutics Announces Appointment of Dr. Jo Viney and Domenic Ferrante to its Board of Directors
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced the appointment of Dr. Jo Viney and Domenic Ferrante to its Board of Directors.
Finch Therapeutics Raises $53 Million to Advance Microbiome-Based Therapies for Recurrent C. Difficile, Autism and other Disease Areas
Finch Therapeutics Group, Inc. announced the completion of a $53 million Series C financing.
Finch Therapeutics Receives Fast Track Designation for the Investigation of Full-Spectrum Microbiota as a Treatment for Children with Autism Spectrum Disorder
Finch Therapeutics Group, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to its Full-Spectrum Microbiota® therapy for the treatment of children with Autism Spectrum Disorder.
Finch Therapeutics’ Investigational Drug CP101 Granted Breakthrough Therapy Designation from FDA for Recurrent C. Difficile Infection
Designation to accelerate Finch’s efforts to provide an effective therapy for patients fighting recurrent C. difficile infection.
After Unity Biotechnology chief executive officer Keith Leonard was on CNBC’s “Power Lunch,” touting the company’s therapeutic approach to longevity and aging, company shares soared almost 18 percent.
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
Finch Therapeutics Group, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has issued six new patents to Finch covering its Full-Spectrum Microbiota (FSM) and Rationally-Selected Microbiota (RSM) product platforms.
Finch Therapeutics Expands Senior Leadership Team with Appointments of Dr. Ulrich Thienel as Chief Medical Officer and Gregory Perry as Chief Financial Officer
Dr. Thienel will lead the clinical development of Finch’s Full-Spectrum Microbiota™ and Rationally-Selected Microbiota™ platforms, while Mr. Perry will provide strategic financial and operational leadership at Finch.
Finch Therapeutics closed on an oversubscribed Series B financing worth $36 million.
Two privately-held biotechs have merged to tackle recurrent C. difficile infections.
OpenBiome Partnering With Finch Therapeutics To Enable FDA Approval Of A Fecal Transplant Treatment For Recurrent C. Difficile Infection